The goal of this clinical trial is to test the effect of high-dose radiation therapy after initial chemotherapy in patients with locally advanced pancreatic cancer. The main question it aims to answer is:
• For patients with locally advanced pancreatic cancer that responded to initial chemotherapy (stayed stable or decreased in size), will high-dose RT (radiation therapy) contribute to improving treatment outcomes, enhancing quality of life, or increasing overall survival rates?
Participants will:
* Undergo an optional tumor biopsy. * Be treated with high dose radiation therapy. * Complete quality of life questionnaires. * Donate research blood samples.
Have a histological or cytological diagnosis of LAPC.
Have pancreatic tumour <8.0 cm in greatest axial dimension at the time of treatment planning but final determination of eligibility will be based upon satisfying the radiation normal tissue constraints.
Eastern Cooperative Oncology Group (ECOG) performance status ≤1 (Karnofsky ≥70%).
Life expectancy of greater than 6 months, as judged by the investigator.
Metastatic disease at the time of registration
Age<18.
Patients who have had prior systemic treatment (chemotherapy or any other anti-cancer agent) in the metastatic setting.
Prior radiotherapy to the upper abdomen region that would result in overlap of RT volume for the current study.